Cell and Gene Therapy in Parkinson's Disease Pipeline Drugs Report 2025: Emerging Innovations, Clinical Advancements, and Future Outlook by DelveInsight

DelveInsight's "Cell and Gene Therapy in Parkinson's Disease Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Cell and Gene Therapy in Parkinson's Disease pipeline landscape. It covers the Cell and Gene Therapy in Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cell and Gene Therapy in Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cell and Gene Therapy in Parkinson's Disease Pipeline? Click here to explore the therapies and trials making headlines @ Cell and Gene Therapy in Parkinson's Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Cell and Gene Therapy in Parkinson's Disease Pipeline Report

* DelveInsight's Cell and Gene Therapy in Parkinson's Disease Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Cell and Gene Therapy in Parkinson's Disease treatment.
* The leading Cell and Gene Therapy in Parkinson's Disease Companies, such as Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences and others.
* Promising Cell and Gene Therapy in Parkinson's Disease Therapies such as BRT-DA01, AB-1005, HB-adMSCs, ANPD 001 , and others.

Want to know which companies are leading innovation in Cell and Gene Therapy in Parkinson's Disease? Dive into the full pipeline insights @ Cell and Gene Therapy in Parkinson's Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Cell and Gene Therapy in Parkinson's Disease Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Cell and Gene Therapy in Parkinson's Disease Pipeline Report also highlights the unmet needs with respect to the Cell and Gene Therapy in Parkinson's Disease.

Cell and Gene Therapy in Parkinson's Disease Overview

According to the Parkinson's Foundation, Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing (dopaminergic) neurons in a specific area of the brain called the substantia nigra. Because Parkinson's disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson's disease: Stage I, Stage II, Stage III, Stage IV, and Stage V.

Cell and Gene Therapy in Parkinson's Disease Emerging Drugs Profile

* BRT-DA01: BlueRock Therapeutics

Bemdaneprocel (BRT-DA01) is an investigational cell therapy developed for the treatment of Parkinson's disease, designed to restore dopamine-producing neurons that are lost due to the disease. This therapy is derived from pluripotent stem cells and involves the surgical implantation of dopamine neuron precursors into the brain, specifically targeting the putamen, a critical area for motor function. Currently, the drug is in the Phase III stage of development to treat Parkinson's Disease.

* AB-1005: Asklepios BioPharmaceutical

AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 containing the human glial cell line-derived neurotrophic factor (AAV2-GDNF) transgene, which allows for stable and continuous expression of GDNF in localized regions of the brain after direct neurosurgical injection with MRI-monitored convection enhanced delivery. GDNF is a homodimer that is a distantly related member of the transforming growth factor- superfamily. In midbrain neuronal cell cultures, recombinant human GDNF promoted the survival and morphological differentiation of dopaminergic neurons and increased their high-affinity dopamine uptake. GDNF has long been evaluated as a potential disease modifying neurorestorative treatment for diseases, such as Parkinson's, marked by progressive degeneration of midbrain dopaminergic neurons. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Parkinson's disease.

* HB-adMSCs: Hope Biosciences

Hope Biosciences Adipose Derived Mesenchymal Stem Cells (HB-adMSCs) is in clinical development for the treatment of Parkinson's disease (PD). The exact mechanism of action (MOA) by which HB-adMSCs exert their therapeutic effects in PD is not fully elucidated. However, mesenchymal stem cell therapies in general are thought to work through various mechanisms. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Parkinson's Disease.

* ANPD 001: Aspen Neuroscience

ANPD001 is an investigational autologous cell therapy developed by Aspen Neuroscience for the treatment of Parkinson's disease (PD). This therapy aims to replace lost dopamine neurons by using dopamine neuronal precursor cells (DANPCs) derived from patient-specific induced pluripotent stem cells (iPSCs). The iPSCs are generated from the patient's own skin cells, ensuring a personalized treatment approach that minimizes the risk of immune rejection and eliminates the need for immunosuppressive drugs, which can be poorly tolerated in older populations. Currently, the drug is in the Phase I/II stage of development to treat Parkinson's Disease.

If you're tracking ongoing Cell and Gene Therapy in Parkinson's Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Cell and Gene Therapy in Parkinson's Disease Treatment Drugs [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Cell and Gene Therapy in Parkinson's Disease Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Cell and Gene Therapy in Parkinson's Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cell and Gene Therapy in Parkinson's Disease Treatment.
* Cell and Gene Therapy in Parkinson's Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cell and Gene Therapy in Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cell and Gene Therapy in Parkinson's Disease market.

Cell and Gene Therapy in Parkinson's Disease Companies

Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences and others.

Cell and Gene Therapy in Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Cell and Gene Therapy in Parkinson's Disease Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Cell and Gene Therapy in Parkinson's Disease Pipeline Report covers it all - check it out now @ Cell and Gene Therapy in Parkinson's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Cell and Gene Therapy in Parkinson's Disease Pipeline Report

* Coverage- Global
* Cell and Gene Therapy in Parkinson's Disease Companies- Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences and others.
* Cell and Gene Therapy in Parkinson's Disease Therapies- BRT-DA01, AB-1005, HB-adMSCs, ANPD 001 , and others.
* Cell and Gene Therapy in Parkinson's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cell and Gene Therapy in Parkinson's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Cell and Gene Therapy in Parkinson's Disease Treatment landscape in this detailed analysis @ Cell and Gene Therapy in Parkinson's Disease Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Cell and Gene Therapy in Parkinson's Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cell and Gene Therapy in Parkinson's Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BRT-DA01: BlueRock Therapeutics
* Mid Stage Products (Phase II)
* AB-1005: Asklepios BioPharmaceutical
* Early Stage Products (Phase I/II)
* ANPD 001: Aspen Neuroscience
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Cell and Gene Therapy in Parkinson's Disease Key Companies
* Cell and Gene Therapy in Parkinson's Disease Key Products
* Cell and Gene Therapy in Parkinson's Disease- Unmet Needs
* Cell and Gene Therapy in Parkinson's Disease- Market Drivers and Barriers
* Cell and Gene Therapy in Parkinson's Disease- Future Perspectives and Conclusion
* Cell and Gene Therapy in Parkinson's Disease Analyst Views
* Cell and Gene Therapy in Parkinson's Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cell-and-gene-therapy-in-parkinsons-disease-pipeline-drugs-report-2025-emerging-innovations-clinical-advancements-and-future-outlook-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.